Aflibercept

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease[1][2][3].

Product Specifications

CAS Number

[862111-32-8]

Product Name Alternative

VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1

UNSPSC

12352203

Target

VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/aflibercept.html

Purity

97.90

Solubility

10 mM in DMSO

Smiles

[Aflibercept]

Molecular Weight

(96.9 kDa)

References & Citations

[1]Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014 Oct;98 (10) :1448-52.|[2]Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor) -Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52 (8) :2637-2648.|[3]Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin. 2021 Sep;42 (9) :1437-1448.